Davis V, Rosenbloom AL: Metabolic effects of antipsychotic drugs. Pediatric Diabetes. 2006, 7 (3): 176-186. 10.1111/j.1399-543X.2006.00178.x.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity : Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27 (2): 596-601. 10.2337/diacare.27.2.596.
Varley CK, McClellan J: Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. Journal of the American Medical Association. 2009, 302 (16): 1811-1812. 10.1001/jama.2009.1558.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association. 2009, 302 (16): 1765-1773. 10.1001/jama.2009.1549.
Veldhuis JD, Johnson ML: Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. Journal of Clinical Endocrinology and Metabolism. 1988, 67 (1): 116-123. 10.1210/jcem-67-1-116.
Frantz AG: Prolactin. The New England Journal of Medicine. 1978, 198: 201-207. 10.1056/NEJM197801262980408.
Bevan JS: Interpreting prolactin levels: Implications for the management of large pituitary lesions. British Journal of Neurosurgery. 1991, 5 (1): 3-6. 10.3109/02688699108998439.
Lenton EA, Brook LM, Sobowale O, Cooke ID: Prolactin concentrations in normal menstrual cycles and conception cycles. Clinical Endocrinology. 1979, 10 (4): 383-391. 10.1111/j.1365-2265.1979.tb02093.x.
Gudelsky GA: Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology. 1981, 6 (1): 3-16. 10.1016/0306-4530(81)90044-5.
Arita J, Kimura F: Direct inhibitory effect of long term estradiol treatment on dopamine synthesis in tuberoinfundibular dopaminergic neurons: in vitro studies using hypothalamic slices. Endocrinology. 1987, 121 (2): 692-698. 10.1210/endo-121-2-692.
Kukstas LA, Domec C, Bascles L, Bonnet J, Verrier D, Israel J-M, Vincent J-D: Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 1991, 129 (2): 1101-1103. 10.1210/endo-129-2-1101.
Fideleff HL, Boquete HR, Suárez MG, Azaretzky M: Prolactinoma in children and adolescents. Hormone Research. 2009, 72 (4): 197-205. 10.1159/000236081.
Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, Riecher-Rössler A: Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004, 64 (20): 2291-2314. 10.2165/00003495-200464200-00003.
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry. 2002, 63 (9): 763-771. 10.4088/JCP.v63n0903.
Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N: Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. British Journal of Clinical Pharmacology. 2000, 49 (supplement 1): 5S-13S.
Pappagallo M, Silva R: The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. Journal of Child and Adolescent Psychopharmacology. 2004, 14 (3): 359-371. 10.1089/cap.2004.14.359.
Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology. 1999, 9 (4): 239-245. 10.1089/cap.1999.9.239.
Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. Journal of the American Academy of Child and Adolescent Psychiatry. 1999, 38 (8): 960-965. 10.1097/00004583-199908000-00011.
Holford L, Peter E, van der Walt A: Risperidone for behavior disorders in children with mental retardation, preliminary data. Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP '00). 2000, October
Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB: Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry. 2000, 39 (3): 292-299. 10.1097/00004583-200003000-00010.
Jordan MP: Ziprasidone-associated galactorrhea in a female teenager. Journal of the American Academy of Child and Adolescent Psychiatry. 2003, 42 (1): 4-5. 10.1097/00004583-200301000-00004.
Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL: Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. Journal of Child and Adolescent Psychopharmacology. 1997, 7 (1): 65-69. 10.1089/cap.1997.7.65.
Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry. 2003, 64 (11): 1362-1369. 10.4088/JCP.v64n1113.
Holzer L, Eap CB: Risperidone-induced symptomatic hyperprolactinemia in adolescents. Journal of Clinical Psychopharmacology. 2006, 26 (2): 167-171. 10.1097/01.jcp.0000203194.58087.9a.
Hellings JA, Zarcone JR, Valdovinos MG, Reese RM, Gaughan E, Schroeder SR: Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2005, 15 (6): 885-892. 10.1089/cap.2005.15.885.
Madhusoodanan S, Moise D: Risperidone-induced hyperprolactinemia in adolescents: a case series. Journal of Clinical Psychiatry. 2006, 67 (7): 1110-1113. 10.4088/JCP.v67n0714.
Handen BL, Hardan AY: Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2006, 45 (8): 928-935. 10.1097/01.chi.0000223312.48406.6e.
Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, de Leon J: Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009, 33: 1496-1501. 10.1016/j.pnpbp.2009.08.009.
Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM: A trial of quetiapine compared with risperidone in the treatment of 1st onset psychosis among 15- to 18-year-old adolescents. International Clinical Psychopharmacology. 2010, 25: 1-6. 10.1097/YIC.0b013e3283320511.
Roke Y, van Harten PN, Boot AM, Buitelaar JK: Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. Journal of Child and Adolescent Psychopharmacology. 2009, 19 (4): 403-414. 10.1089/cap.2008.0120.
Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and Genomics. 2009, 19 (5): 373-382. 10.1097/FPC.0b013e328329a60f.
Duval F, Guillon M-S, Mokrani M-C, Crocq M-A, Duarte FG: Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. Psychoneuroendocrinology. 2008, 33 (2): 255-259. 10.1016/j.psyneuen.2007.10.010.
Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, Van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ: Prolactin release in children treated with risperidone: Impact and role of CYP2D6 metabolism. Journal of Clinical Psychopharmacology. 2007, 27 (1): 52-57. 10.1097/JCP.0b013e31802e68d5.
Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU: Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. Journal of Child and Adolescent Psychopharmacology. 2009, 19 (5): 563-573. 10.1089/cap.2009.0051.
Howes OD, Wheeler MJ, Meaney A-M, O'Keane V, Fogelman I, Blake G, Murray RM, Smith S: Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. Journal of Clinical Psychopharmacology. 2005, 25 (3): 259-261. 10.1097/01.jcp.0000162798.87249.4d.
Meaney AM, O'Keane V: Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Research. 2007, 93 (1–3): 136-143. 10.1016/j.schres.2007.01.013.
Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA: A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. Journal of Clinical Psychiatry. 2010, 71 (3): 338-347. 10.4088/JCP.08m04595gre.
Biller BMK, Baum HBA, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A: Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. Journal of Clinical Endocrinology and Metabolism. 1992, 75 (3): 692-697. 10.1210/jc.75.3.692.
Seriwatanachai D, Krishnamra N, van Leeuwen JPTM: Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. Journal of Cellular Biochemistry. 2009, 107 (4): 677-685. 10.1002/jcb.22161.
Emiliano ABF, Fudge JL: From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology. 2004, 29 (5): 833-846. 10.1038/sj.npp.1300412.
Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006, 26 (6): 748-758. 10.1592/phco.26.6.748.